PerkinElmer Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The company was founded in 1931 and is based in Waltham, Massachusetts.
PKI Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Perkinelmer Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Perkinelmer Inc ranked in the 27th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Perkinelmer Inc, consider:
The company's debt burden, as measured by earnings divided by interest payments, is 4.01 -- which is good for besting 53.12% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
87% of the company's capital comes from equity, which is greater than 71.92% of stocks in our cash flow based forecasting set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
RMD, ZTS, CPIX, XRAY, and IONS can be thought of as valuation peers to PKI, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
A report by The Insight Partner's on the Gene Expression Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the
It may be indelicate to talk about beneficiaries of a deadly global pandemic, but the reality is that COVID-19 has created an unexpected surge in business for many life sciences companies. In the case of PerkinElmer (PKI), while the recent demand for real-time PCR workstations and kits, liquid handling systems,...
Stephen Simpson, CFA on Seeking Alpha | September 28, 2020
Needham has upgraded PerkinElmer ([[PKI]] +4.0%) to Buy from Hold with a $139 price target (17% upside), also adding the stock to his Conviction Buy list.The analyst is impressed with the "strong operational performance" of the company's Diagnostics segment as the company reported almost doubled earnings in Q2.The company said...